Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium

Leukemia Research

Volumn 36, Issue 12, 2012, Pages 1500-1504

  Mascarenhas, John ^a   Heaney, Mark L ^b   Najfeld, Vesna ^a   Hexner, Elizabeth ^c   Abdel Wahab, Omar ^b   Rampal, Raajit ^b   Ravandi, Farhad ^d   Petersen, Bruce ^a   Roboz, Gail ^e   Feldman, Eric ^e   Podoltsev, Nikolai ^f   Douer, Dan ^b   Levine, Ross ^b   Tallman, Martin ^b   Hoffman, Ronald ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute myeloid leukemia; Blast phase; Clinical trial; Myeloproliferative neoplasm; Response criteria

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLOOD ANALYSIS; BONE MARROW BIOPSY; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); CYTOGENETICS; DISEASE COURSE; GENE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; JAK2 GENE; KARYOTYPING; LEUKEMIC TRANSFORMATION; MALIGNANT TRANSFORMATION; MOLECULAR GENETICS; MULTICENTER STUDY (TOPIC); MYELOPROLIFERATIVE NEOPLASM; MYELOPROLIFERATIVE NEOPLASM IN BLAST PHASE; PRIORITY JOURNAL; SPLEEN; TREATMENT RESPONSE; VALIDATION STUDY;

BLAST CRISIS; BLOOD CELLS; BONE MARROW; CLINICAL TRIALS AS TOPIC; GENETIC MARKERS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MYELOABLATIVE AGONISTS; MYELOPROLIFERATIVE DISORDERS; SPLEEN; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 84868206008     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.08.013     Document Type: Article

References (39)

1. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., et al. WHO classification of tumours of haematopoietic and lymphoid tissues 2008.
2. Mesa R.A., Verstovsek S., Cervantes F., Barosi G., Reilly J.T., Dupriez B., et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 2007, 31(6):737-740.
3. Gangat N., Wolanskyj A.P., McClure R.F., Li C.Y., Schwager S., Wu W., et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia 2007, 21(2):270-276.
4. Barbui T. The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?. Semin Hematol 2004, 41(2 Suppl. 3):15-17.
5. Mesa R.A., Li C.Y., Ketterling R.P., Schroeder G.S., Knudson R.A., Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 2005, 105(3):973-977.
6. Gangat N., Wolanskyj A.P., Schwager S.M., Hanson C.A., Tefferi A. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol 2007, 138(3):354-358.
7. Finazzi G., Caruso V., Marchioli R., Capnist G., Chisesi T., Finelli C., et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005, 105(7):2664-2670.
8. Passamonti F., Rumi E., Pietra D., Elena C., Boveri E., Arcaini L., et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010, 24(9):1574-1579.
9. Tam C.S., Nussenzveig R.M., Popat U., Bueso-Ramos C.E., Thomas D.A., Cortes J.A., et al. The natural history and treatment outcome of blast phase BCR-ABL-myeloproliferative neoplasms. Blood 2008, 112(5):1628-1637.
10. Mascarenhas J., Navada S., Malone A., Rodriguez A., Najfeld V., Hoffman R. Therapeutic options for patients with myelofibrosis in blast phase. Leuk Res 2010, 34(9):1246-1249.
11. Ciurea S.O., de Lima M., Giralt S., Saliba R., Bueso-Ramos C., Andersson B.S., et al. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biol Blood Marrow Transplant 2010, 16(4):555-559.
12. Eghtedar A., Verstovsek S., Estrov Z., Burger J., Cortes J., Bivins C., et al. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012, 119(20):4614-4618.
13. Tefferi A., Barosi G., Mesa R.A., Cervantes F., Deeg H.J., Reilly J.T., et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006, 108(5):1497-1503.
14. Barosi G., Birgegard G., Finazzi G., Griesshammer M., Harrison C., Hasselbalch H.C., et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood 2009, 113(20):4829-4833.
15. Barosi G., Bordessoule D., Briere J., Cervantes F., Demory J.L., Dupriez B., et al. Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood 2005, 106(8):2849-2853.
16. Cheson B.D., Bennett J.M., Kopecky K.J., Buchner T., Willman C.L., Estey E.H., et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003, 21(24):4642-4649.
17. Cheson B.D., Greenberg P.L., Bennett J.M., Lowenberg B., Wijermans P.W., Nimer S.D., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108(2):419-425.
18. Thepot S., Itzykson R., Seegers V., Raffoux E., Quesnel B., Chait Y., et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood 2010, 116(19):3735-3742.
19. Manoharan A., Horsley R., Pitney W.R. The reticulin content of bone marrow in acute leukaemia in adults. Br J Haematol 1979, 43(2):185-190.
20. Thiele J., Kvasnicka H.M., Facchetti F., Franco V., van der Walt J., Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005, 90(8):1128-1132.
21. Zhang S.J., Rampal R., Manshouri T., Patel J., Mensah N., Kayserian A., et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood;119(19): 2012, 4480-4485.
22. Klampfl T., Harutyunyan A., Berg T., Gisslinger B., Schalling M., Bagienski K., et al. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood 2011, 118(1):167-176.
23. Abdel-Wahab O., Manshouri T., Patel J., Harris K., Yao J., Hedvat C., et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010, 70(2):447-452.
24. Harutyunyan A., Klampfl T., Cazzola M., Kralovics R. p53 lesions in leukemic transformation. N Engl J Med 2011, 364(5):488-490.
25. Guglielmelli P., Barosi G., Specchia G., Rambaldi A., Lo Coco F., Antonioli E., et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009, 114(8):1477-1483.
26. Barosi G., Bergamaschi G., Marchetti M., Vannucchi A.M., Guglielmelli P., Antonioli E., et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 2007, 110(12):4030-4036.
27. Campbell P.J., Griesshammer M., Dohner K., Dohner H., Kusec R., Hasselbalch H.C., et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 2006, 107(5):2098-2100.
28. Tefferi A., Lasho T.L., Huang J., Finke C., Mesa R.A., Li C.Y., et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008, 22(4):756-761.
29. Thoennissen N.H., Krug U.O., Lee D.H., Kawamata N., Iwanski G.B., Lasho T., et al. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood 2010, 115(14):2882-2890.
30. Mesa R.A., Li C.Y., Ketterling R.P., Schroeder G.S., Knudson R.A., Tefferi A. JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia. Leuk Res 2006, 30(11):1457-1460.
31. Theocharides A., Boissinot M., Girodon F., Garand R., Teo S.S., Lippert E., et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007, 110(1):375-379.
32. Campbell P.J., Baxter E.J., Beer P.A., Scott L.M., Bench A.J., Huntly B.J., et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 2006, 108(10):3548-3555.
33. Beer P.A., Ortmann C.A., Stegelmann F., Guglielmelli P., Reilly J.T., Larsen T.S., et al. Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms. Haematologica 2010, 95(12):2153-2156.
34. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010, 24(6):1128-1138.
35. Wang J.C., Chen W., Nallusamy S., Chen C., Novetsky A.D. Hypermethylation of the P15INK4b and P16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation. Br J Haematol 2002, 116(3):582-586.
36. Dingli D., Schwager S.M., Mesa R.A., Li C.Y., Dewald G.W., Tefferi A. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis. Cancer 2006, 106(9):1985-1989.
37. Caramazza D., Begna K.H., Gangat N., Vaidya R., Siragusa S., Van Dyke D.L. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia 2011, 25(1):82-88.
38. Gangat N., Caramazza D., Vaidya R., George G., Begna K., Schwager S., et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011, 29(4):392-397.
39. Ni H., Barosi G., Rondelli D., Hoffman R. Studies of the site and distribution of CD34+ cells in idiopathic myelofibrosis. Am J Clin Pathol 2005, 123(6):833-839.